relevant system failures since neither doctors nor people have all of the data necessary to make suitable judgments of product top quality and authorized tort therapies are sluggish, inefficient, and extremely costly. The changes for the CGMP regulation would require manufacturers to extend [Website page 52644] their top quality systems to incorpor